$STOK
Stoke Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023060224 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $2.802M $3.308M
YoY Change -14.26% 13.87%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.61M $10.27M
YoY Change 13.06% 3.28%
% of Gross Profit
Research & Development $21.78M $20.27M
YoY Change 3.41% 0.81%
% of Gross Profit
Depreciation & Amortization $619.0K $640.0K
YoY Change 1.64% 64.95%
% of Gross Profit
Operating Expenses $32.39M $30.54M
YoY Change 6.39% 1.63%
Operating Profit -$27.23M
YoY Change 0.32%
Interest Expense $2.587M $2.651M
YoY Change 74.92% 166.43%
% of Operating Profit
Other Income/Expense, Net $41.00K $2.692M
YoY Change -2.38% 159.59%
Pretax Income -$26.96M -$24.54M
YoY Change 5.08% -6.02%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$26.96M -$24.54M
YoY Change 5.08% -6.01%
Net Earnings / Revenue -962.1% -741.9%
Basic Earnings Per Share -$0.55
Diluted Earnings Per Share -$0.60 -$0.55
COMMON SHARES
Basic Shares Outstanding 44.65M 44.26M
Diluted Shares Outstanding 44.27M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $201.4M $214.7M
YoY Change -12.28% -14.68%
Cash & Equivalents $191.4M $190.0M
Short-Term Investments $9.952M $24.74M
Other Short-Term Assets $2.561M $4.269M
YoY Change -13.33% -65.99%
Inventory
Prepaid Expenses $11.32M $10.94M
Receivables
Other Receivables
Total Short-Term Assets $215.3M $230.0M
YoY Change -11.77% -13.07%
LONG-TERM ASSETS
Property, Plant & Equipment $5.823M $6.217M
YoY Change -12.76% -13.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $569.0K $600.0K
YoY Change 0.0% 5.45%
Total Long-Term Assets $13.00M $9.870M
YoY Change 8.39% -24.22%
TOTAL ASSETS
Total Short-Term Assets $215.3M $230.0M
Total Long-Term Assets $13.00M $9.870M
Total Assets $228.3M $239.9M
YoY Change -10.83% -13.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.695M $3.076M
YoY Change 121.28% 60.96%
Accrued Expenses $12.96M $12.90M
YoY Change -14.97% -5.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.82M $25.20M
YoY Change -1.83% -12.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.884M $959.0K
YoY Change 64.56% -73.43%
Total Long-Term Liabilities $37.96M $41.69M
YoY Change -4.69% -6.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.82M $25.20M
Total Long-Term Liabilities $37.96M $41.69M
Total Liabilities $68.78M $66.89M
YoY Change -3.43% -8.97%
SHAREHOLDERS EQUITY
Retained Earnings -$401.8M -$374.9M
YoY Change 35.23% 38.08%
Common Stock $5.000K $4.000K
YoY Change 25.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $159.6M $173.0M
YoY Change
Total Liabilities & Shareholders Equity $228.3M $239.9M
YoY Change -10.83% -13.59%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$26.96M -$24.54M
YoY Change 5.08% -6.01%
Depreciation, Depletion And Amortization $619.0K $640.0K
YoY Change 1.64% 64.95%
Cash From Operating Activities -$20.65M -$17.26M
YoY Change -7.71% -21.74%
INVESTING ACTIVITIES
Capital Expenditures $226.0K $390.0K
YoY Change -44.74% -119.21%
Acquisitions
YoY Change
Other Investing Activities $15.00M $15.00M
YoY Change -34.49% -78.35%
Cash From Investing Activities $14.77M $14.62M
YoY Change -34.34% -78.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.347M 560.0K
YoY Change 16986.05% 29.03%
NET CHANGE
Cash From Operating Activities -20.65M -17.26M
Cash From Investing Activities 14.77M 14.62M
Cash From Financing Activities 7.347M 560.0K
Net Change In Cash 1.466M -2.080M
YoY Change 816.25% -104.56%
FREE CASH FLOW
Cash From Operating Activities -$20.65M -$17.26M
Capital Expenditures $226.0K $390.0K
Free Cash Flow -$20.87M -$17.65M
YoY Change -8.38% -11.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001623526
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38938
dei Entity Registrant Name
EntityRegistrantName
Stoke Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1144582
dei Entity Address Address Line1
EntityAddressAddressLine1
45 Wiggins Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
430-8200
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
STOK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44653782
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189977000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113556000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24741000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
116039000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10936000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10932000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4269000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2955000
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
96000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
588000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
230019000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
244070000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3084000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4753000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6217000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6675000
CY2023Q3 us-gaap Assets
Assets
239889000
CY2022Q4 us-gaap Assets
Assets
256067000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3076000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
766000
CY2023Q3 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
13390000
CY2022Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
15748000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8735000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14880000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25201000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31394000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
40730000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36856000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
959000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2968000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
41689000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
39824000
CY2023Q3 us-gaap Liabilities
Liabilities
66890000
CY2022Q4 us-gaap Liabilities
Liabilities
71218000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44293115
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44293115
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39439575
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39439575
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
548033000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
483170000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-147000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1175000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-374891000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297150000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
172999000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
184849000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
239889000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256067000
CY2023Q3 us-gaap Revenues
Revenues
3308000
CY2022Q3 us-gaap Revenues
Revenues
2905000
us-gaap Revenues
Revenues
5978000
us-gaap Revenues
Revenues
9137000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20271000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20109000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60453000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56777000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10271000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9944000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30712000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29540000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
30542000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
30053000
us-gaap Operating Expenses
OperatingExpenses
91165000
us-gaap Operating Expenses
OperatingExpenses
86317000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27234000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27148000
us-gaap Operating Income Loss
OperatingIncomeLoss
-85187000
us-gaap Operating Income Loss
OperatingIncomeLoss
-77180000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2651000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
995000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7321000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1643000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
125000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
125000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2692000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1037000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7446000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1768000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-24542000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26111000
us-gaap Net Income Loss
NetIncomeLoss
-77741000
us-gaap Net Income Loss
NetIncomeLoss
-75412000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44266017
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44266017
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39420310
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39420310
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43669987
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43669987
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38716615
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38716615
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-24542000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26111000
us-gaap Net Income Loss
NetIncomeLoss
-77741000
us-gaap Net Income Loss
NetIncomeLoss
-75412000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
232000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-427000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1028000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1535000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
232000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-427000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1028000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1535000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24310000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26538000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76713000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76947000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
217777000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24649000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-516000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4975000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000
CY2022Q1 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
42128000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
169000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
239977000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24652000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-592000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6163000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
326000
CY2022Q2 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
3099000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
224321000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26111000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-427000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5926000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
401000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
204143000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
184849000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22545000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
577000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5887000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
158000
CY2023Q1 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
44743000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
153000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
213822000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-30654000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
219000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6760000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
190195000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-24542000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
232000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6552000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
161000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
401000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
172999000
us-gaap Profit Loss
ProfitLoss
-77741000
us-gaap Profit Loss
ProfitLoss
-75412000
us-gaap Depreciation
Depreciation
1845000
us-gaap Depreciation
Depreciation
937000
stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
-236000
stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
-60000
us-gaap Share Based Compensation
ShareBasedCompensation
19199000
us-gaap Share Based Compensation
ShareBasedCompensation
17064000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
1669000
stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
1446000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
824000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3655000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2059000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3729000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2272000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
53916000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60418000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9493000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
206190000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1387000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3553000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
92562000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
141371000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
91175000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68372000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
554000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
570000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
367000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
452000
stok Proceeds From Controlled Equity Offering Sales Agreement
ProceedsFromControlledEquityOfferingSalesAgreement
44743000
stok Proceeds From Controlled Equity Offering Sales Agreement
ProceedsFromControlledEquityOfferingSalesAgreement
45344000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45664000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46366000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
76421000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31499000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114125000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145464000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190546000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113965000
stok Right Of Use Assets Recognized In Exchange For Operating Leases
RightOfUseAssetsRecognizedInExchangeForOperatingLeases
1802000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
406000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113965000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189977000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113396000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190546000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
525000
CY2023Q3 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5144000
CY2022Q4 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6601000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2498000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2359000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
472000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24888000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
147000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24741000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
117214000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1175000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
116039000
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4749000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5754000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
527000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0470
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
96340
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
49200000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y5M12D
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
509000
CY2023Q3 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
13390000
CY2022Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
15748000
CY2018Q3 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
23000
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q3 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
900000
CY2018Q3 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.03
CY2018Q3 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2018-12-10
CY2018Q4 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
2485
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q4 stok Number Of Renewal Option To Extend Operating Lease Terms
NumberOfRenewalOptionToExtendOperatingLeaseTerms
1
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2018Q4 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
200000
CY2018Q4 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.025
CY2018Q4 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2019-05-01
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
634000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2608000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
172000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3414000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
97000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3317000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3084000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2498000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
819000
CY2023Q3 stok Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted
OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted
3317000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6552000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5926000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19199000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17064000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-24542000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26111000
us-gaap Net Income Loss
NetIncomeLoss
-77741000
us-gaap Net Income Loss
NetIncomeLoss
-75412000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44266017
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44266017
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39420310
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39420310
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43669987
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43669987
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38716615
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38716615
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
stok-20230930_cal.xml Edgar Link unprocessable
0000950170-23-060224-index-headers.html Edgar Link pending
0000950170-23-060224-index.html Edgar Link pending
0000950170-23-060224.txt Edgar Link pending
0000950170-23-060224-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stok-20230930.htm Edgar Link pending
stok-20230930.xsd Edgar Link pending
stok-ex31_1.htm Edgar Link pending
stok-ex31_2.htm Edgar Link pending
stok-ex32_1.htm Edgar Link pending
stok-ex32_2.htm Edgar Link pending
stok-20230930_def.xml Edgar Link unprocessable
stok-20230930_lab.xml Edgar Link unprocessable
stok-20230930_pre.xml Edgar Link unprocessable
stok-20230930_htm.xml Edgar Link completed